Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OMEICOS Therapeutics

Request full access

Prevention and treatment of cardiovascular diseases

Berlin, GermanyFounded 2013Biotech & Life Sciences

About OMEICOS Therapeutics

OMEICOS Therapeutics is a biotechnology company focused on developing innovative therapies for cardiovascular, inflammatory, and mitochondrial diseases, which have high unmet medical needs. The company leverages its proprietary approach to target critical cell protective pathways and utilizes its industry-leading expertise in omega-3 fatty acid metabolism. OMEICOS's lead compound, OMT-28, has shown promising results and is a key part of their therapeutic pipeline. The company primarily serves the healthcare and pharmaceutical markets, aiming to provide advanced treatment options that address significant gaps in current medical therapies. OMEICOS operates on a business model that includes research and development, clinical trials, and partnerships with other biotech firms and pharmaceutical companies. Revenue is generated through licensing agreements, collaborations, and potential future sales of their therapeutic products.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
73.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Risk Management, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANT✓Other financing Jul 2023 $2.8M — Undisclosed ↗
SERIES C✓Equity / VC Nov 2018 $17M $68M Forbion Capital Partners · Vesalius Biocapital Partners —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearProfitMargin
2026 —
2025 —
2024 —
2023 —
2022 —
2021 —
2020 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

OMEICOS Therapeutics website traffic

Latest recorded traffic for OMEICOS Therapeutics is 230 monthly website visits, down 43.9% over the last three months. OMEICOS Therapeutics's team grew 0% over the past year.

Latest monthly visits230 3-month web change-43.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

OMEICOS Therapeutics in the Berlin ecosystem

Live from Dealroom

The OMEICOS Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

Series A5 investors entered at this stage

  • Vesalius Biocapital Partners
  • KfW
  • IBB Ventures
  • VC Fonds Kreativwirtschaft
  • Remiges Ventures

Series B and later1 investor entered at this stage

  • Forbion Capital Partners

Other known investors3 additional known investors

  • Max Delbrück Center for Molecular Medicine
  • Helmholtz Association - Helmholtz Gemeinschaft
  • German Federal Ministry of Research, Technology and Space
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇩🇪 Germany75%
🇨🇭 Switzerland25%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about OMEICOS Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OMEICOS Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.